In today’s market, healthcare providers are struggling to find reliable, low-cost solutions to reduce the financial and environmental burden of providing excellent care. FDA-regulated reprocessed medical devices are not only safe and effective, but use of such devices saves considerable financial resources, as well as dramatically reduces hospital-generated waste.
Under the strong oversight of the U.S. Food and Drug Administration (FDA), members of the Association of Medical Device Reprocessors (AMDR)1 reprocess (or clean, test, refurbish, package and sterilize, among other steps) select medical devices labeled by the original manufacturer as for “single-use.” These devices include orthopedic blades, compression sleeves, pulse oximeter sensors, cardiac catheters and laparoscopic surgical instruments. For over ten years, AMDR’s members have been providing America’s hospitals with reprocessed medical devices that are safe, FDA-regulated, lower-cost and environmentally-responsible.
AMDR promotes and protects the legal, regulatory and other trade interests of the nation’s third-party medical device reprocessing industry. As part of that mission, AMDR supports the proper reprocessing of medical devices labeled for “single-use” (or SUDs) ensuring that reprocessed devices are as safe and as effective as original equipment. Further, AMDR promotes reprocessing as a means of cutting healthcare costs and promoting environmental responsibility.
The reprocessing industry has demonstrated an exemplary record of safety over the last decade, when FDA extended its medical device manufacturer requirements to reprocessors. Since that time, informed health care facilities have increasingly supported the practice of reprocessing. AMDR’s members currently serve America’s finest medical facilities, including all institutions ranked by U.S. News & World Report as the nation’s “Honor Roll” hospitals.2
Reprocessed medical devices are regulated by FDA, and as such have been found to be “as safe and as effective as a new device.”3 FDA has long considered third-party “reprocessors of devices labeled for single-use to be [medical device] manufacturers.”4 In 2000, the agency began subjecting reprocessors to all of its requirements for device manufacturers.5 FDA explained that a “manufacturer can market a device for one more single use from a raw material that was a previously-used, [single-use device] if that device meets the specifications of the device described in the market clearance.”6
The reprocessing of medical devices originally labeled for “single use” is subject to a stringent, comprehensive regulatory scheme. In short, “FDA believes that reprocessed [single-use devices] that meet FDA’s regulatory requirements are as safe and effective as a new device.”7
FDA-regulated reprocessed devices are much less costly – typically about half the cost of an original device.8 This 50% savings incorporates all of the third-party reprocessors’ costs, including research and development, equipment and materials, staff, and the cost of recycling devices when they have reached the end of their life, among many other operational costs.
As far back as 2000, the U.S. Government Accountability Office (GAO) found that facilities using reprocessed devices saved between $200,000 and $1 million annually, on average.9 Currently, reprocessors estimate that a typical 200 bed hospital, if taking advantage of a reprocessors’ full product line, can save between $600,000 and $1 million dollars a year, and divert between 5,000 and 15,000 pounds of waste from landfills.10 The supply chain is typically one of the most costly departments of a hospital and the savings generated by reprocessed medical devices provides healthcare executives the opportunity to allocate limited resources towards other operational needs such as additional nursing hires, upgrades to technology, indigent care offerings, and necessary improvements to infrastructure.
Regulated medical waste (RMW), or “red bag waste,” is another wasteful expenditure that typically costs hospitals 5 to 10 times more to dispose than regular solid waste. Fortunately, many medical devices that end up in a hospital’s RMW are actually eligible to be reprocessed multiple times, eliminating the needless generation of more RMW while also reducing unnecessary waste disposal costs. Also, ninety-five percent (95%) of the reprocessed devices that have reached the end of their life are recycled versus sent to landfills. AMDR’s members recycle a variety of raw materials from devices that cannot be reprocessed or have reached their maximum number of reprocessing cycles, including stainless steel, aluminum, titanium, gold, polycarbonate and polyurethane parts.
Reprocessing has allowed some hospitals to divert over 8,000 pounds of RMW from landfills each year, while larger systems can divert more than 50,000 pounds. Groups like the American Nursing Association, the Association of periOperative Registered Nurses, and Practice Greenhealth have recognized or endorsed reprocessing as a way to reduce waste.11
The benefits of reprocessing medical devices are truly multi-fold; device users get a “single-use” device that, in terms of aesthetics and functionality, is equivalent to its predecessor; healthcare executive are able to generate savings for the hospital and reduce medical waste; and patients receive the latest in surgical care technology with uncompromised safety and at the same time allow for the maximization of limited healthcare resources.
The ongoing paradigm shift in healthcare – to provide the highest quality service at the lowest affordable cost – has substantially raised expectations for hospitals. The third-party reprocessing industry has been a catalyst for such a change since its inception, and AMDR is confident that reprocessed SUDs will continue to play an increasingly important role in our healthcare system.
Daniel J. Vukelich, Esq. is the President of the Association of Medical Device Reprocessors (AMDR). Mr. Vukelich has been with AMDR since 2000. AMDR represents approximately 95 percent of the third-party medical device reprocessing done in the U.S. today. In addition to representing the reprocessing industry in the U.S., Mr. Vukelich also has represented the device reprocessing industry before state regulatory agencies, the European Commission and Parliament, Health Canada, and other international bodies.